title: Cancer drug discovery faces the FACT.
abstract: In this issue of Science Translational Medicine, Gasparian et al. use a clever cell-based screen to identify a family of DNA-binding small molecules-curaxins-that inhibit tumor cell growth and division. The curaxins' mechanism of action pinpoints a new chromatin-remodeling factor as a therapeutic target for cancer.
authors.affiliation: Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA 02115, USA.
authors.forename: Giulio F
authors.initials: GF
authors.lastname: Draetta
authors.forename: Ronald A
authors.initials: RA
authors.lastname: Depinho
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D006609:High Mobility Group Proteins / Q000378:metabolism*; D006801:Humans; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D035602:Transcriptional Elongation Factors / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D006609:High Mobility Group Proteins; D016328:NF-kappa B; C073537:SSRP1 protein, human; D035602:Transcriptional Elongation Factors; D016159:Tumor Suppressor Protein p53